US EditionTrump Expected to Sign Executive Order Urging More Research Into Psychedelic Ibogaine
The order would open federal funding for studies on PTSD and traumatic brain injuries while leaving ibogaine classified as a Schedule I drug.
- President Donald Trump is expected to sign an executive order this week encouraging federal research into ibogaine, a psychedelic substance used abroad to treat post-traumatic stress disorder, sources told CBS News.
- Because ibogaine is illegal in the United States, Americans have been traveling to unregulated clinics in Mexico and the Caribbean to seek treatment, operating without U.S. regulatory oversight.
- A 2023 review of 24 studies involving 705 people found that while ibogaine reduced withdrawal symptoms, toxicity to the heart and risk of death were "worrying," with at least 27 fatalities reported.
- Federal officials seek to determine whether the drug is "snake oil" or a legitimate treatment, while Texas Gov. Greg Abbott has already approved $50 million for state-level research into the compound.
- Despite the research push, the administration does not plan to reclassify ibogaine as a Schedule I substance, though news of the order prompted Enveric Biosciences stock to surge around 45% and Psyence Biomedical to reach $6.95.
24 Articles
24 Articles
Trump Reportedly About to Issue Executive Order on Ibogaine Research
President Donald Trump is reportedly planning to issue an executive order as soon as this week signaling the administration’s willingness to explore the therapeutic benefits and safety of the psychedelic substance ibogaine. CBS News reported on April 16 that while the administration doesn’t plan to reschedule the psychedelic out of Schedule I of the Controlled Substances Act (CSA) at this time, the move is “meant to open the door to federal fund…
New Hamburg independent
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged recent reports that the U.S. administration is preparing an executive…
Veterans are traveling to Mexico to Get Ibogaine for PTSD, now Trump Plans to Order Study on Psychedelic Drug
President Donald Trump is expected to sign an executive order in the next days aimed at expanding U.S. research into ibogaine, a psychedelic compound that some clinics abroad use to treat post-traumatic stress disorder, traumatic brain injury, addiction, depression and anxiety, according to CBS News.
Trump expected to sign executive order urging more research into psychedelic ibogaine
President Donald Trump is expected to sign an executive order in the coming days that will encourage more research into the psychedelic ibogaine, according to a person familiar with the order.
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
